Iambic Therapeutics, Inc. (NasdaqGS: IAM)
Health Care · Biotechnology · US
$13.10
-11.73% today · -30.7% 1Y
Iambic Therapeutics, Inc. (NasdaqGS: IAM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $620.95M and employs 171 people.
Over the last twelve months the share price has lost 30.7%, trading between 10.17 and 25.00.
Tweenvest scores Iambic Therapeutics, Inc. across four factors: quality 50/100, value 67/100. Its strongest factor is value.
IAM price history
Key figures
- Market cap
- $620.95M
- Revenue (TTM)
- $18.25M
- P/E
- -12.97
- EPS
- -3.57
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $25.00
- 52-week low
- $10.17
- Avg volume (3M)
- —
- Shares outstanding
- 47.40M
- Employees
- 171
- Next earnings
- —
About Iambic Therapeutics, Inc.
Iambic Therapeutics, Inc. develops AI driven platform for drug discovery. It combines proprietary AI-driven platforms with the expertise of experienced drug discovery scientists to identify, design, and optimize novel therapeutic candidates across a range of disease areas. The company was founded by Thomas Miller and Fred Manby on October 14, 2019 and is headquartered in San Diego, CA.
- ISIN
- US45076A1016
- Founded
- 2019
- Listed since
- Oct 15, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Immix Biopharma, Inc.NasdaqCM: IMMX | $626.92M | $7.48 | -4.59% |
| DBV Technologies S.A.ENXTPA: DBV | $624.05M | €1.80 | -3.69% |
| Bicara Therapeutics Inc.NasdaqGM: BCAX | $622.71M | $9.38 | -2.29% |
| Lepu Biopharma Co., Ltd.SEHK: 2157 | $620.99M | HK$2.70 | -3.57% |
| Shenzhen Weiguang Biological Products Co., Ltd.SZSE: 002880 | $620.89M | CN¥18.26 | -3.23% |
| Arbutus Biopharma CorporationNasdaqGS: ABUS | $619.30M | $4.04 | -1.22% |
| Crescent Biopharma, Inc.NasdaqCM: CBIO | $605.64M | $14.15 | -1.53% |
| Surrozen, Inc.NasdaqCM: SRZN | $602.54M | $31.61 | -0.19% |